Status:
COMPLETED
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and ...
Eligibility Criteria
Inclusion
- INCLUSION:
- Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis:
- AFP \> 200 mg/dL;
- A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or
- A tumor mass confirmed by arteriography.
- Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging.
- EXCLUSION:
- Pediatric patients under the age of 18 will be excluded from consideration from this study.
- Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible.
- Pregnant and breastfeeding patients.
- Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00081094
Start Date
September 1 2003
End Date
September 1 2005
Last Update
April 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110